Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany

Phase 4

Completed

Conditions: Relapsing-Remitting Multiple Sclerosis

Interventions: Drug: dimethyl fumarate

First Posted Date: 2014-04-29

Last Posted Date: 2017-04-18

Lead Sponsor: Biogen

Target Recruit Count: 214

Registration Number: NCT02125604

Locations: 🇩🇪
Research Site, Siegen, Germany

A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIB017 (PEGylated Interferon Beta-1a)
Drug: Placebo

First Posted Date: 2014-04-29

Last Posted Date: 2014-04-29

Lead Sponsor: Biogen

Target Recruit Count: 69

Registration Number: NCT02125578

Locations: 🇺🇸
Research Site, Phoenix, Arizona, United States

Pilot Tape Harvesting Study

Completed

Conditions: Subacute Cutaneous Lupus Erythematosus
Healthy
Discoid Lupus Erythematosus
Atopic Dermatitis

Interventions: Procedure: Skin Taping
Procedure: Blood Sampling
Procedure: Skin Biopsy

First Posted Date: 2014-04-29

Last Posted Date: 2016-09-28

Lead Sponsor: Biogen

Target Recruit Count: 37

Registration Number: NCT02125695

Locations: 🇺🇸
Research Site, Boston, Massachusetts, United States

Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus

Phase 1

Completed

Conditions: Systemic Lupus Erythematosus
Healthy Volunteers

Interventions: Drug: BIIB059 (litifilimab)
Drug: Placebo

First Posted Date: 2014-04-08

Last Posted Date: 2023-01-31

Lead Sponsor: Biogen

Target Recruit Count: 109

Registration Number: NCT02106897

Locations: 🇺🇸
Research Site, Duncansville, Pennsylvania, United States

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

Phase 2

Completed

Conditions: Relapsing Forms of Multiple Sclerosis

Interventions: Biological: tetanus diphtheria toxoids vaccine
Drug: dimethyl fumarate
Biological: 23-valent pneumococcal polysaccharide vaccine
Drug: non-pegylated interferon
Biological: meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)

First Posted Date: 2014-03-27

Last Posted Date: 2017-06-02

Lead Sponsor: Biogen

Target Recruit Count: 71

Registration Number: NCT02097849

Locations: 🇺🇸
Research Site, San Antonio, Texas, United States

Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis

Phase 4

Completed

Conditions: Relapsing-Remitting Multiple Sclerosis

Interventions: Drug: dimethyl fumarate
Drug: acetylsalicylic acid
Drug: ASA-Placebo

First Posted Date: 2014-03-18

Last Posted Date: 2016-12-28

Lead Sponsor: Biogen

Target Recruit Count: 241

Registration Number: NCT02090413

Locations: 🇬🇧
Research Site, Swansea, United Kingdom

Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate

Phase 4

Withdrawn

Conditions: Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis

Interventions: Drug: dimethyl fumarate

First Posted Date: 2014-03-18

Last Posted Date: 2015-09-07

Lead Sponsor: Biogen

Registration Number: NCT02090348

Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen

Completed

Conditions: Relapsing-Remitting Multiple Sclerosis
Clinical Isolated Syndrome (CIS)
Multiple Sclerosis

Interventions: Device: interferon beta-1a

First Posted Date: 2014-03-04

Last Posted Date: 2017-01-27

Lead Sponsor: Biogen

Target Recruit Count: 40

Registration Number: NCT02076841

Locations: 🇨🇭
Research Site, Wil, Switzerland

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIB061
Drug: Placebo
Drug: 14C-BIIB061

First Posted Date: 2014-02-25

Last Posted Date: 2015-02-02

Lead Sponsor: Biogen

Target Recruit Count: 39

Registration Number: NCT02071121

Locations: 🇺🇸
Research Site, Madison, Wisconsin, United States

An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)

Phase 1

Completed

Conditions: Spinal Muscular Atrophy

Interventions: Drug: nusinersen

First Posted Date: 2014-02-03

Last Posted Date: 2021-02-16

Lead Sponsor: Biogen

Target Recruit Count: 47

Registration Number: NCT02052791

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
UT Southwestern Medical Center - Children's Medical Center Dallas, Dallas, Texas, United States
🇺🇸
University of Utah School of Medicine, Salt Lake City, Utah, United States

and more 1 locations

Home Terms & Conditions Privacy Policy